```html

Rectal Cancer – Comprehensive Medical Guide

Overview

Rectal cancer is a type of malignant tumor that originates in the lining of the rectum—the last 12 cm (about 5 inches) of the large intestine, ending at the anus. It belongs to the broader group of colorectal cancers, which together account for about 1 in 23 new cancer cases in the United States.

• Incidence: According to the CDC, there were ≈ 44,000 new cases of rectal cancer diagnosed in the U.S. in 2022, representing roughly 28 % of all colorectal cancers.
• Mortality: About 8,000 deaths occurred in the same year, making it the third leading cause of cancer death for both men and women.
• Age & gender: The median age at diagnosis is 68 years; men are diagnosed slightly more often than women (ratio ≈ 1.3:1).
• Geography: Higher rates are observed in high‑income countries, likely reflecting diet, lifestyle, and screening practices.

Early detection dramatically improves outcomes; the 5‑year survival rate exceeds 90 % when the disease is confined to the rectal wall, but falls below 15 % once it has spread to distant organs.

Symptoms

Rectal cancer may develop silently for years. When symptoms appear, they can vary based on tumor size, location, and whether it has spread.

• Changes in bowel habits – persistent diarrhea, constipation, or a sense of incomplete evacuation lasting more than 2 weeks.
• Rectal bleeding – bright red blood on toilet paper, in stool, or mixed with stool.
• Dark or tarry stools (melena) – indicates bleeding higher in the colon but can occur with large rectal tumors.
• Abdominal cramps or pain – cramping may be intermittent; constant pain may suggest obstruction.
• Unexplained weight loss – loss of appetite and > 5 % body weight without trying.
• Fatigue or anemia – chronic blood loss can cause iron‑deficiency anemia, leading to tiredness.
• Feeling of fullness or bloating – especially after meals.
• Changes in stool caliber – thin or pencil‑shaped stools may indicate a narrowing of the rectal lumen.
• Persistent urge to have a bowel movement (tenesmus) even when the rectum is empty.
• Unexplained fever – may signal infection from a perforated tumor.

Because many of these signs overlap with benign conditions (hemorrhoids, IBS, infections), any persistent symptom should be evaluated by a health professional.

Causes and Risk Factors

Rectal cancer results from the accumulation of genetic mutations in the cells lining the rectum. These mutations can be inherited, arise spontaneously, or be induced by environmental exposures.

Genetic and hereditary factors

• Lynch syndrome (hereditary non‑polyposis colorectal cancer) – a mismatch‑repair gene defect that raises lifetime colorectal cancer risk to 70‑80 %.
• Familial adenomatous polyposis (FAP) – APC gene mutation leading to hundreds of polyps; almost all develop cancer by age 40 without prophylactic surgery.
• Inflammatory bowel disease (IBD) – longstanding ulcerative colitis or Crohn’s disease of the colon/rectum increases risk 2‑5‑fold.

Lifestyle and environmental factors

• Age – risk rises sharply after 50 years.
• Diet – high consumption of red/processed meat, low fiber, and low fruit/vegetable intake.
• Obesity – body‑mass index (BMI) ≥ 30 is linked to a 20‑30 % higher risk.
• Physical inactivity – sedentary lifestyle contributes to risk.
• Smoking – long‑term tobacco use raises risk by ≈ 30 %.
• Heavy alcohol use – ≥ 2 drinks per day (women) or ≥ 3 drinks per day (men) increases risk.
• Diabetes – type 2 diabetes is associated with a modest increase in risk.

Diagnosis

When rectal cancer is suspected, a stepwise diagnostic work‑up is performed to confirm the disease, stage its extent, and guide treatment.

Initial evaluation

• Medical history & physical exam – includes digital rectal examination (DRE) to feel for masses.
• Stool‑based tests – fecal immunochemical test (FIT) or guaiac‑based fecal occult blood test (FOBT) can detect occult blood but are not definitive.

Definitive testing

1. Colonoscopy with biopsy – gold standard; allows direct visualization, measurement, and procurement of tissue for pathology.
2. Imaging for staging
   • Pelvic magnetic resonance imaging (MRI) – best for assessing depth of wall invasion and involvement of mesorectal lymph nodes.
   • Endorectal ultrasound (EUS) – useful for early tumors (< T2).
   • CT scan of abdomen & pelvis – evaluates distant spread (lung, liver).
   • Chest CT – screens for pulmonary metastases.
3. Laboratory studies
   • Complete blood count (CBC) – can reveal anemia.
   • Carcinoembryonic antigen (CEA) – tumor marker useful for monitoring response and recurrence.

Staging

Rectal cancer is staged using the AJCC TNM system (Tumor, Node, Metastasis). Accurate staging is crucial because it determines whether surgery alone suffices or if neoadjuvant (pre‑operative) therapy is required.

Treatment Options

Treatment is individualized based on stage, tumor location, patient health, and personal preferences. Multidisciplinary care—oncology, surgery, radiation oncology, gastroenterology, nutrition, and supportive services—is the standard.

Early‑stage disease (Stage 0‑I)

• Local excision – transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS) for small, well‑differentiated tumors.
• Radical surgery – low anterior resection (LAR) or abdominoperineal resection (APR) when deeper invasion is present.

Locally advanced disease (Stage II‑III)

1. Neoadjuvant chemoradiation – typically 5‑fluorouracil (5‑FU) or capecitabine combined with 45–50 Gy of pelvic radiation over 5‑6 weeks. Shrinks tumor, increases chance of sphincter‑preserving surgery.
2. Surgical resection
   • Low anterior resection (LAR) – preserves anal sphincter, creates a colorectal anastomosis.
   • Abdominoperineal resection (APR) – required if tumor involves the sphincter; results in permanent colostomy.
3. Adjuvant chemotherapy – 6–12 months of oxaliplatin‑based regimens (FOLFOX or CAPOX) after surgery improves disease‑free survival.

Metastatic disease (Stage IV)

• Systemic chemotherapy – combination regimens (FOLFOX, FOLFIRI) ± targeted agents (bevacizumab, cetuximab) based on KRAS/NRAS/BRAF status.
• Immunotherapy – pembrolizumab or nivolumab for tumors with high microsatellite instability (MSI‑H) or mismatch repair deficiency (dMMR).
• Local therapies – hepatic metastasectomy, radiofrequency ablation, or stereotactic body radiotherapy (SBRT) when limited liver disease.
• Palliative care – focuses on symptom control, quality of life, and psychosocial support.

Lifestyle & supportive measures

• Nutrition counseling – high‑protein, high‑fiber diet (if tolerated) to maintain weight.
• Physical activity – at least 150 min of moderate‑intensity exercise per week improves outcomes.
• Smoking cessation and alcohol moderation.
• Psychological support – counseling, support groups, and survivorship programs.

Living with Rectal Cancer

Adapting daily life after diagnosis involves practical strategies that address physical, emotional, and social dimensions.

Managing bowel function

• Keep a food and symptom diary to identify triggers for diarrhea or constipation.
• Consider low‑residue diet during radiation to reduce urgency.
• Use stool‑bulking agents (psyllium) or antidiarrheal meds (loperamide) as directed.
• Pelvic floor rehabilitation can improve continence after sphincter‑preserving surgery.

Stoma care (if APR performed)

• Work with an enterostomal therapist to learn appliance fitting and skin protection.
• Carry spare supplies; practice changing the pouch in a private setting before emergencies.
• Stay hydrated and monitor for signs of dehydration (dry mouth, low urine output).

Emotional wellbeing

• Seek counseling or join cancer survivor groups (American Cancer Society, CancerCare).
• Mind‑body techniques—guided imagery, meditation, yoga—can reduce anxiety and fatigue.
• Communicate openly with family and employers about needed accommodations.

Follow‑up schedule

After curative treatment, most guidelines (e.g., NCCN) recommend:

• Physical exam, CEA level, and colonoscopy at 3‑6 months post‑treatment.
• Subsequent colonoscopies every 3‑5 years if no polyps are found.
• CT imaging of chest/abdomen/pelvis every 6–12 months for the first 3 years, then annually.

Adhering to this schedule enables early detection of recurrence.

Prevention

Although not all rectal cancers can be prevented, evidence‑based measures markedly lower risk.

• Screening – Begin regular colonoscopy at age 45 (or earlier with family history). A negative colonoscopy reduces risk for at least 10 years.
• Diet – Eat ≥ 5 servings of fruits/vegetables daily; choose whole grains; limit red and processed meats to < 18 oz/week.
• Maintain healthy weight – Aim for BMI 18.5–24.9.
• Exercise – ≥ 150 minutes of moderate activity weekly.
• Avoid tobacco – Smoking cessation reduces risk for many cancers, including rectal.
• Limit alcohol – ≤ 1 drink/day for women, ≤ 2 drinks/day for men.
• Control chronic conditions – Good glycemic control in diabetes; manage IBD with regular surveillance colonoscopies.
• Vaccination – HPV vaccination may lower risk of anal/rectal cancers linked to HPV infection.

Complications

If left untreated or if treatment complications arise, several serious problems can develop.

• Obstruction – Tumor can block the rectum, causing severe abdominal pain, vomiting, and inability to pass gas or stool.
• Perforation – Tumor erosion may lead to a hole in the bowel, causing peritonitis—a surgical emergency.
• Bleeding and anemia – Chronic blood loss leads to fatigue, shortness of breath, and need for transfusions.
• Metastatic spread – Common sites include liver, lungs, and peritoneum; advanced disease reduces survival.
• Fistula formation – Abnormal connections between the rectum and adjacent organs (bladder, vagina) causing infection and urinary problems.
• Radiation‑induced injury – Proctitis, strictures, or chronic diarrhea.
• Surgical complications – Wound infection, anastomotic leak, urinary retention, or sexual dysfunction.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic, CDC, National Cancer Institute, NCCN Guidelines, American Cancer Society, WHO, *Lancet Oncology* (2022), *Journal of Clinical Oncology* (2023). All information is for educational purposes and does not replace professional medical advice.

```